We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Fevertree Drinks plc (FEVR) Ordinary 0.25p

Sell:907.00p Buy:911.00p 0 Change: 15.00p (1.64%)
FTSE AIM 100:0.12%
Market closed Prices as at close on 25 June 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:907.00p
Buy:911.00p
Change: 15.00p (1.64%)
Market closed Prices as at close on 25 June 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:907.00p
Buy:911.00p
Change: 15.00p (1.64%)
Market closed Prices as at close on 25 June 2025 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

HL comment (5 June 2025)

No recommendation - No news or research item is a personal recommendation to deal. All investments can fall as well as rise in value so you could get back less than you invest.

Fevertree trading so far in 2025 has been in line with group expectations. Momentum in the US has been strong, with underlying brand growth remaining ahead of the competition.

Europe continues to deliver good momentum across multiple markets, however, sales in Germany remain muted.

As part of the partnership agreement, Fevertree and Molson Coors will equally share the 10% US tariff on UK imports and are actively working together to mitigate the short-term tariff impact.

The group said it remains "comfortable’’ with its full-year expectations of low single-digit revenue growth and underlying cash profit (EBITDA) margins of around 12%.

Around £42.5mn of the ongoing £100mn share buyback programme has been completed.

The shares remained flat in early trading.

Our view

Fevertree’s trading so far this year has been in line with group expectations, helped by good progress in the US and most of Europe. That’s given the group confidence to reiterate its full-year guidance, although the target of low single-digit revenue growth was hardly stretching to begin with.

Fevertree’s progress in the US to date has been impressive, becoming the number one brand in both the tonic and ginger beer categories. This market has already grown to become the group’s largest region by sales. But given the vast size of the US, there’s still a lot of room for growth.

Momentum in the US continues to build following the strategic partnership with Molson Coors. Fevertree handed over equity in the business, and in return, it’s getting access to Coors’ broad US production, distribution and customer network. Having the second-largest US brewer on your side is no bad thing.

While the 10% US tariff on UK imports will be a headwind in the short term, the cost is set to be shared equally between Fevertree and Molson Coors. The impact is expected to ease over the medium term, as local US production ramps up.

Fevertree continues to expand its drinks portfolio with new products, and non-tonic mixers had grown to around 45% of total sales at the last count. These new offerings open the door to different types of drinkers, drastically increasing the number of customers it has to go after.

But there are some challenges to be wary of.

UK sales continued to trend in the wrong direction last year. It turns out there is a cap on how much premium tonic you can sell, and it looks like Fevertree has reached it in its home market. Successful international expansion will be critical to continued growth.

While we’re positive on the long-term outlook for the Coors partnership, there’s a lot of work to be done to get it up and running. Operational creases will likely need to be ironed out as Coors takes over US production, so we wouldn't rule out disappointment on the profit front as the year progresses.

Last we heard, the balance sheet was in good shape with the group sitting on net cash of £96mn and there’s currently a prospective 1.9% dividend yield on offer. The partnership may reduce demands on Fevertree’s cash over time, potentially clearing room for further shareholder returns. But as always, no shareholder returns are guaranteed.

The long-term outlook is better than it has been for some time. But even with the recently announced partnership, we see plenty of trip hazards in the near term. Potential investors should expect a bumpy ride.

Environmental, social and governance (ESG) risk

The food and beverage industry tends to be medium-risk in terms of ESG though some segments like agriculture, tobacco and spirits fall into the high-risk category. Product governance is a key risk industry-wide, especially in areas with strict quality and safety requirements. Labour relations and supply chain management are also industry-wide risks, with other issues varying by sub-sector.

According to Sustainalytics, Fevertree’s management of ESG risk is average.

The group doesn’t use plastic bottles but instead uses glass or cans from a portion of recycled materials. As such, the group’s products are completely recyclable, however, they are energy-intensive to mould and make. Fevertree also claims its range of mixers sold in the UK are carbon neutral. However, no concrete scope emission reduction targets appear to be in place.

Fevertree key facts

  • Forward price/earnings ratio (next 12 months): 35.8

  • Ten year average forward price/earnings ratio: 44.2

  • Prospective dividend yield (next 12 months): 1.9%

  • Ten year average prospective dividend yield: 1.0%

All ratios are sourced from LSEG Datastream, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.

This article is original Hargreaves Lansdown content, published by Hargreaves Lansdown. It was correct as at the date of publication, and our views may have changed since then. Unless otherwise stated estimates, including prospective yields, are a consensus of analyst forecasts provided by Refinitiv. These estimates are not a reliable indicator of future performance. Yields are variable and not guaranteed. Investments rise and fall in value so investors could make a loss.

This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.


Previous Fevertree Drinks plc updates

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.